Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin

Journal of Immunology

Volumn 189, Issue 1, 2012, Pages 245-252

  Luan, Xudong ^a   Lu, Qingyu ^a   Jiang, Yinan ^a   Zhang, Senyan ^a   Wang, Qing ^a   Yuan, Huihui ^b   Zhao, Wenming ^b   Wang, Jiawei ^a   Wang, Xinquan ^a  

^a TSINGHUA UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; CRYSTALLIZATION; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; OSTEOPROTEGERIN; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RANK LIGAND;

EID: 84862884060     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103387     Document Type: Article

References (48)

1. Boyce, B. F., and L. Xing. 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473: 139-146.
2. Theill, L. E., W. J. Boyle, and J. M. Penninger. 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20: 795-823. (Pubitemid 34293440)
3. Theoleyre, S., Y. Wittrant, S. K. Tat, Y. Fortun, F. Redini, and D. Heymann. 2004. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15: 457-475. (Pubitemid 39550455)
4. Dougall, W. C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M. E. Tometsko, C. R. Maliszewski, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev. 13: 2412-2424. (Pubitemid 29453612)
5. Kong, Y. Y., H. Yoshida, I. Sarosi, H. L. Tan, E. Timms, C. Capparelli, S. Morony, A. J. Oliveira-dos-Santos, G. Van, A. Itie, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
6. Li, J., I. Sarosi, X. Q. Yan, S. Morony, C. Capparelli, H. L. Tan, S. McCabe, R. Elliott, S. Scully, G. Van, et al. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97: 1566-1571. (Pubitemid 30118482)
7. Simonet, W. S., D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang, R. Lüthy, H. Q. Nguyen, S. Wooden, L. Bennett, T. Boone, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319. (Pubitemid 27199902)
8. Anandarajah, A. P. 2009. Role of RANKL in bone diseases. Trends Endocrinol. Metab. 20: 88-94.
9. Kearns, A. E., S. Khosla, and P. J. Kostenuik. 2008. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29: 155-192. (Pubitemid 351519689)
10. Takayanagi, H. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7: 292-304. (Pubitemid 46480961)
11. Fata, J. E., Y. Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R. A. Moorehead, R. Elliott, S. Scully, E. B. Voura, D. L. Lacey, et al. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50.
12. Jones, D. H., T. Nakashima, O. H. Sanchez, I. Kozieradzki, S. V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C. V. Hojilla, et al. 2006. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
13. Schramek, D., A. Leibbrandt, V. Sigl, L. Kenner, J. A. Pospisilik, H. J. Lee, R. Hanada, P. A. Joshi, A. Aliprantis, L. Glimcher, et al. 2010. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102.
14. Hanada, R., A. Leibbrandt, T. Hanada, S. Kitaoka, T. Furuyashiki, H. Fujihara, J. Trichereau, M. Paolino, F. Qadri, R. Plehm, et al. 2009. Central control of fever and female body temperature by RANKL/RANK. Nature 462: 505-509.
15. Tanaka, S. 2007. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system. Am. J. Nephrol. 27: 466-478. (Pubitemid 47482003)
16. Ikeda, T., M. Kasai, M. Utsuyama, and K. Hirokawa. 2001. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142: 1419-1426. (Pubitemid 32299669)
17. Lum, L., B. R. Wong, R. Josien, J. D. Becherer, H. Erdjument-Bromage, J. Schlöndorff, P. Tempst, Y. Choi, and C. P. Blobel. 1999. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274: 13613-13618.
18. Ito, S., K. Wakabayashi, O. Ubukata, S. Hayashi, F. Okada, and T. Hata. 2002. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J. Biol. Chem. 277: 6631-6636. (Pubitemid 34968464)
19. Lam, J., C. A. Nelson, F. P. Ross, S. L. Teitelbaum, and D. H. Fremont. 2001. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 108: 971-979. (Pubitemid 32946071)
20. Leibbrandt, A., and J. M. Penninger. 2008. RANK/RANKL: regulators of immune responses and bone physiology. Ann. N. Y. Acad. Sci. 1143: 123-150.
21. Tanaka, S., I. Nakamura, J. Inoue, H. Oda, and K. Nakamura. 2003. Signal transduction pathways regulating osteoclast differentiation and function. J. Bone Miner. Metab. 21: 123-133. (Pubitemid 41184293)
22. Yamaguchi, K., M. Kinosaki, M. Goto, F. Kobayashi, E. Tsuda, T. Morinaga, and K. Higashio. 1998. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J. Biol. Chem. 273: 5117-5123. (Pubitemid 28108672)
23. Yasuda, H., N. Shima, N. Nakagawa, S. I. Mochizuki, K. Yano, N. Fujise, Y. Sato, M. Goto, K. Yamaguchi, M. Kuriyama, et al. 1998. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337. (Pubitemid 28510154)
24. Cheng, T., N. J. Pavlos, C. Wang, J. W. Tan, J. M. Lin, J. Cornish, M. H. Zheng, and J. Xu. 2009. Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation. Mol. Endocrinol. 23: 35-46.
25. Ito, S., and T. Hata. 2004. Crystal structure of RANK ligand involved in bone metabolism. Vitam. Horm. 67: 19-33. (Pubitemid 39753658)
26. Ta, H. M., G. T. Nguyen, H. M. Jin, J. Choi, H. Park, N. Kim, H. Y. Hwang, and K. K. Kim. 2010. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc. Natl. Acad. Sci. USA 107: 20281-20286.
27. Liu, C., T. S. Walter, P. Huang, S. Zhang, X. Zhu, Y. Wu, L. R. Wedderburn, P. Tang, R. J. Owens, D. I. Stuart, et al. 2010. Structural and functional insights of RANKL-RANK interaction and signaling. J. Immunol. 184: 6910-6919.
28. Leslie, A. 1992. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 26.
29. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta. Crystallogr. D Biol. Crystallogr. 50: 760-763.
30. McCoy, A. J., R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, and R. J. Read. 2007. Phaser crystallographic software. J. Appl. Cryst. 40: 658-674. (Pubitemid 47080256)
31. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60: 2126-2132. (Pubitemid 41742764)
32. Adams, P. D., R. W. Grosse-Kunstleve, L. W. Hung, T. R. Ioerger, A. J. McCoy, N. W. Moriarty, R. J. Read, J. C. Sacchettini, N. K. Sauter, and T. C. Terwilliger. 2002. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58: 1948-1954. (Pubitemid 35337293)
33. Naismith, J. H., and S. R. Sprang. 1998. Modularity in the TNF-receptor family. Trends Biochem. Sci. 23: 74-79. (Pubitemid 28085231)
34. Schneeweis, L. A., D. Willard, and M. E. Milla. 2005. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J. Biol. Chem. 280: 41155-41164. (Pubitemid 41832168)
35. Emery, J. G., P. McDonnell, M. B. Burke, K. C. Deen, S. Lyn, C. Silverman, E. Dul, E. R. Appelbaum, C. Eichman, R. DiPrinzio, et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273: 14363-14367. (Pubitemid 28319153)
36. Truneh, A., S. Sharma, C. Silverman, S. Khandekar, M. P. Reddy, K. C. Deen, M. M. McLaughlin, S. M. Srinivasula, G. P. Livi, L. A. Marshall, et al. 2000. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275: 23319-23325. (Pubitemid 30646233)
37. Vitovski, S., J. S. Phillips, J. Sayers, and P. I. Croucher. 2007. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282: 31601-31609. (Pubitemid 350044899)
38. Johnstone, R. W., A. J. Frew, and M. J. Smyth. 2008. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8: 782-798.
39. Cha, S. S., B. J. Sung, Y. A. Kim, Y. L. Song, H. J. Kim, S. Kim, M. S. Lee, and B. H. Oh. 2000. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275: 31171-31177.
40. Hymowitz, S. G., H. W. Christinger, G. Fuh, M. Ultsch, M. O'Connell, R. F. Kelley, A. Ashkenazi, and A. M. de Vos. 1999. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4: 563-571. (Pubitemid 29531136)
41. Mongkolsapaya, J., J. M. Grimes, N. Chen, X. N. Xu, D. I. Stuart, E. Y. Jones, and G. R. Screaton. 1999. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol. 6: 1048-1053. (Pubitemid 29519600)
42. Hymowitz, S. G., M. P. O'Connell, M. H. Ultsch, A. Hurst, K. Totpal, A. Ashkenazi, A. M. de Vos, and R. F. Kelley. 2000. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39: 633-640. (Pubitemid 30065031)
43. Shahbazi, S., P. J. Lenting, C. Fribourg, V. Terraube, C. V. Denis, and O. D. Christophe. 2007. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J. Thromb. Haemost. 5: 1956-1962. (Pubitemid 47288955)
44. Zannettino, A. C., C. A. Holding, P. Diamond, G. J. Atkins, P. Kostakis, A. Farrugia, J. Gamble, L. B. To, D. M. Findlay, and D. R. Haynes. 2005. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J. Cell. Physiol. 204: 714-723. (Pubitemid 40934668)
45. Baud'huin, M., L. Duplomb, S. Téletchéa, C. Charrier, M. Maillasson, M. Fouassier, and D. Heymann. 2009. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J. Biol. Chem. 284: 31704-31713.
46. Ando, K., K. Mori, F. Rédini, and D. Heymann. 2008. RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr. Drug Discov. Technol. 5: 263-268.
47. Tanaka, S., K. Nakamura, N. Takahasi, and T. Suda. 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208: 30-49. (Pubitemid 41746383)
48. Wells, J. A., and C. L. McClendon. 2007. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009. (Pubitemid 350273630)